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An asymptomatic 67-year-old man with rising prostate spe-cific antigen (PSA) was referred to our center to perform 
an 18F-Choline positron emission computed tomography (PET/
CT) scan. He had a prostatic adenocarcinoma [Gleason score 8 
(4 + 4), stage T1cN0M0] treated 9 years ago by curative radia-
tion therapy (RT; 74 Gy) and hormonal therapy for 6 months. 
Initial PSA was 10.7 ng/ml. The PSA follow-up was between 
2.44 and 1.55 ng/ml. After 7 years, PSA raised at 4 ng/ml and 
a CT of thorax, abdomen, and pelvis was performed. It showed 
a bronchus-centered lung mass of 46 mm in the middle right 
lob, sharply delineated, round shaped and with the finger-in-
glove sign, radiologically diagnosed as a bronchocele (Fig. 1). 
Abdomen and pelvis CT explorations were negative, especially 
on prostatic, pelvic lymph nodes, and skeletal areas. Few months 
after, PSA decreased at 2.7 ng/ml. Considering the mucocele as 
benign, conservative follow-up with thoracic CT imaging was 
decided instead of biopsy. One year after, the bronchocele was 
perfectly stable in size and shape on follow-up thoracic CT, but 
PSA raised again at 3.5 ng/ml and prostatic magnetic resonance 
imaging was then performed. A late and slowly rising PSA level 
may be a sign of only prostatic local failure after curative RT.1 
Magnetic resonance imaging remained atypical without recur-
rence criteria and systematic prostatic biopsies were planned 
accordingly. According to French guidelines,2 18F-Choline PET/
CT scan was then performed to localize the occult biochemical 
recurrence. It remained negative in frequently involved areas 
in recurrent prostate cancer such as prostatic bed, pelvic lymph 
nodes, or skeleton. Patient could be considered with biochemi-
cal relapse only, but unexpectedly, there was an intense homoge-
neous 18F-Choline uptake into the known bronchocele which was 
perfectly stable in size with millimeter accuracy (Fig. 2). In our 
hypothesis, at this point, this phospholipidic hypermetabolism 
into the mucocele might be compatible with a mucus infection, a 
slowly evolutive malignant lung tumor such as a mucinous cyst-
adenocarcinoma,3 a neuroendocrine carcinoma,4 a metastasis,5 
or even a lung surfactant accumulation into the bronchocele, 
as 18F-Choline could be metabolized as phosphatidylcholine 
in mucus production.6 18F-fluorodeoxyglucose (FDG) PET/CT 
scan was then performed to characterize the pulmonary lesion 
whether glucose metabolism in that abnormality favored a benign 
or malignant process.7 It showed a homogeneous FDG uptake 
into the bronchocele and no other abnormal uptake in particular 
in the prostatic, pelvic lymph node, or skeletal areas. (Fig. 3). 
This glucidic hypermetabolism was compatible with a mucus 
infection or a proliferating tumor. Prostatic biopsies were per-
formed but no local recurrence was found. Performed in view of 
the abnormal FDG uptake,8 CT guided biopsy of the pulmonary 
mass, showed surprisingly adenocarcinoma cells with positive 
anti-prostatic acid phosphatase antibody immunohistochemical 
staining, and lead to the final diagnosis of a solitary lung metas-
tasis of prostatic adenocarcinoma. On multidisciplinary medical 
staff decision and with patient agreement, surgical excision of the 
metastasis was performed. Right middle lobe lobectomy piece 
is shown on Figure 4. Macroscopically, the tumor was whitish, 
lobular, and sharply delineated. Microscopically, the tumoral 
glands were fused, lined by a single layer of malignant cells with 
polyadenoid architecture (Fig. 4). Immunohistochemical stain-
ing by prostatic acid phosphatase and PSA antibody was positive 
on all tumoral cells.
DISCUSSION
Any continuously rising PSA levels following a nadir 
after RT indicate local recurrence, systemic metastatic spread, 
or both.1 Although androgen deprivation therapy (ADT) is a 
popular option for management of recurrent prostate carci-
noma displaying progression, some men will progress and 
may benefit from salvage local treatment9 such as radical 
prostatectomy, cryotherapy, interstitial RT, or high-intensity 
focused ultrasound.1 In the absence of documented metasta-
ses, men are often offered a salvage local treatment.
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ADT alone after a recurrence of prostate carcinoma 
is primarily reserved for patients with systemic disease. 
Currently, no consensus exists on the ideal timing or PSA 
cut-point for institution of therapy. Some clinicians advocate 
for early ADT, before the development of clinical metastases, 
whereas others prefer to wait until the development of clini-
cal metastasis.9 It is not clear whether additional treatments 
FIGURE 2. A, 3D Maximum intensity projection 18F-Choline 
positron emission tomography (PET) anterior view with 
salivary, hepatic, pancreatic, renal, and vesical physiologi-
cal uptake. B, Coronal fused 18F-Choline PET/computed 
tomography (CT) on tissular window. C, Axial fused 
18F-Choline PET/CT on lung window centered on the lung 
mass. 18F-Choline PET/CT scan was negative in the prostatic, 
pelvic lymph node, and skeletal areas. There was an intense 
homogeneous 18F-Choline uptake (SUVmax = 9.8) into the 
bronchocele which was perfectly stable in size with a millime-
ter accuracy compared with previous thorax CT scans.
FIGURE 3. A, 3D Maximum intensity projection 
18F-fluorodeoxyglucose (FDG) positron emission tomogra-
phy (PET) anterior view with cerebral, myocardial, hepatic, 
renal, and vesical physiological uptake. B, Coronal fused 18F-
FDG PET/computed tomography (CT) on tissular window. 
C, Axial fused 18F-FDG PET/CT on lung window centered on 
the lung mass. 18F-FDG PET/CT scan was also negative in the 
prostatic, pelvic lymph node, and skeletal areas. There was a 
homogeneous FDG uptake (SUVmax = 6) into the broncho-
cele still stable in size and shape.
FIGURE 1.  Thoracic computed tomography 
(CT) showed lobular and round mass in the right 
middle lobe of 46 × 43 mm (A) with an average 
radiodensity compatible with tissue, blood, or 
sticky liquid (+41 Hounsfield unit) as seen on 
tissular window (B). A bronchus was centering 
the mass (C). Classic finger-in-glove sign was 
observed in lower and distal part of the mass (D). 
Radiological first diagnosis was a bronchocele, 
and follow-up CT at 1 year remained absolutely 
stable with millimeter accuracy.
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given on the basis of rising PSA alone in asymptomatic men 
with prostate cancer increase overall survival.10 A substantial 
proportion of patients with elevated or rising PSA levels after 
initial therapy with curative intent may remain clinically free 
of symptoms for extended periods.1
The literature search did not identify any randomized trials 
of the treatment of PSA-only recurrence. According on guide-
lines,11 hormonal therapy is not routinely recommended for men 
with prostate cancer who have a biochemical relapse unless they 
have symptomatic local disease progression, any proven metas-
tases, or a PSA doubling time of less than 3 months.11
On the other hand, it might be possible that resection 
of identified metastatic lesions could contribute to the man-
agement of a subset of prostate cancer cases, as seen in other 
malignancies. There are two potential patterns of metastatic 
dissemination: a single-step process in which all metastatic 
cancer cells originate from the primary tumor, and a cascade 
process in which metastases metastasize.12 In the cascade 
process theory, early removal of metastases could potentially 
improve patient outcome. Some biochemical remission has 
been reported after resection of lymph nodes metastasis,13 and 
extensive dissection of the pelvic lymph nodes at radical pros-
tatectomy has also been reported to increase biochemical cure 
rates in short-term follow-up.14,15
Solitary lung metastasis of prostate cancer without osse-
ous or lymphatic involvement is very rare, only 18 cases have 
been published.16 This unusual finding presents a therapeutic 
question of the role of metastasectomy, which contributed to 
a complete response in four cases on seven documented in 
literature.16 Those few cases of successful metastasectomy are 
exceptions to “normal” tumor biology and, as such, not gener-
alizable, but it shows that in a very specific subset of patients 
with a low burden of metastases, even if it is usually regarded 
as a manifestation of systemic disease, minimally invasive 
surgery lobectomy or metastasectomy, may be an option and 
should be discussed in treatment strategy.16
 Mucoid impaction is a relatively common finding at 
CT that often manifests as tubular opacities known as the fin-
ger-in-glove sign. This sign most often appears in segmental 
bronchial atresia or cystic fibrosis.5 It may also be observed 
in inflammatory and infectious diseases (allergic broncho-
pulmonary aspergillosis, broncholithiasis, and foreign body 
aspiration), benign neoplastic processes (bronchial hamar-
toma, lipoma, and papillomatosis), and malignancies (bron-
chogenic carcinoma, carcinoid tumor, and metastases).5
In this unusual case, thoracic imaging specialist has 
been mistaken by the atypical and serendipitous presentation 
of the lung mass, with no radiological characteristic of bron-
chogenic carcinoma such as spiculated margins, cavitation, 
vascular convergence, or pleural retraction.17 Diagnosis error 
was even supported by stable follow-up CT in this slowly evo-
luting tumor.
But the size of the lesion should have alert clinicians: 
according to guidelines,17 a lesion of more than 3 cm is not a 
nodule but a lung mass, and must be biopsied first, presuming 
to represent bronchogenic carcinoma until proved otherwise. 
FDG PET/CT is recommended to characterize indeterminate, 
solitary, solid, non-calcified lung nodule of more than 8 mm..8,17
F-Choline is a PET tracer with promising results in the 
detection and evaluation of cancers with low glucose metabo-
lism such as prostate carcinoma, hepatocellular carcinoma, or 
bronchioloalveolar carcinoma.18 F-Choline is a precursor of 
the biosynthesis of phosphatidylcholine, essential component 
of cell membrane phospholipid, and depending on the choline 
kinase activity.19 Choline kinase activity is upregulated in pro-
liferating tumoral cells.19 As a consequence, early trapping of 
F-Choline into tumoral cell membrane phospholipids reflects 
tumoral proliferation.19 F-Choline PET/CT is now often used 
in France to localize biochemical occult recurrence of prostate 
cancer in selected patients.2
In this case, nuclear functional imaging helped to localize 
the biochemical prostate cancer recurrence by ruling out a local 
prostatic, regional nodal, or bone recurrence, and characteriz-
ing a radiological known stable misdiagnosed lesion as a low 
but active and evolutive lesion, with an increased glucidic and 
phospholipidic metabolism. This unusual case underlines the 
usefulness of metabolic and functional imaging characteriza-
tion by Fluorine-18 radiolabeled PET tracers by providing addi-
tional and complementary information to anatomical imaging.
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